Gastroenteropancreatic Neuroendocrine Carcinoma
1 clinical trials · Condition
◉ Watch Gastroenteropancreatic Neuroendocrine Carcinoma
| Record | Firm | Date |
|---|---|---|
| Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors (NCT07006727) | Novartis Pharmaceuticals | 2025-10-16 |
Track Gastroenteropancreatic Neuroendocrine Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.